LEADER 04633nam 2201441z- 450 001 9910580203103321 005 20220706 035 $a(CKB)5690000000012059 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87430 035 $a(oapen)doab87430 035 $a(EXLCZ)995690000000012059 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aTherapeutic Potential of Plant Secondary Metabolites in the Treatment of Diseases and Drug Development 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (334 p.) 311 08$a3-0365-3881-X 311 08$a3-0365-3882-8 330 $aThe importance of natural products, and especially plant secondary metabolites, for the treatment of diseases and drug development has already been obvious in medicine for several thousand years. Thus, this Special Issue of MDPI Biomedicines collects eight top articles from the field as regular full papers in addition to five reviews. All of the published papers are a vibrant source of information on the therapeutic potential of plant secondary metabolites in the treatment of diseases and drug development. 606 $aIndustrial chemistry and chemical engineering$2bicssc 606 $aTechnology: general issues$2bicssc 610 $aalkaloids 610 $aamide bond 610 $aanabolic 610 $aanti-HIV activity 610 $aantimicrobial activity 610 $aantiviral therapy 610 $aartemisinin 610 $abetulinic acid 610 $abevirimat 610 $abioavailability 610 $aBODIPY 610 $acancer 610 $acancer cells 610 $acannabichromene 610 $acannabidiol (CBD) 610 $acannabinoid receptors (CB1 and CB2) 610 $acannabinoids 610 $aCannabis sativa (Cannabis) 610 $acapsaicinoids 610 $acardiometabolic diseases 610 $acell-cycle 610 $achloroquine 610 $aCOVID-19 610 $acurcumin 610 $acurcumin analogues 610 $acurcumin delivery systems 610 $acurcumin derivatives 610 $acytotoxicity 610 $adiabetes 610 $aDuchenne muscular dystrophy 610 $aecdysteroid 610 $aecdysterone 610 $aEGFR 610 $aendocannabinoidome 610 $afluorescent microscopy 610 $afood intake 610 $aHuisgen 1,3-dipolar cycloaddition 610 $ainflammation 610 $aivermectin 610 $alignans 610 $alipid accumulation 610 $alipidomics 610 $alipogenesis 610 $alung cancer 610 $aLXR? 610 $aMAFLD 610 $amalaria 610 $aMas1 610 $amaturation inhibitor 610 $amembrane fusion 610 $ametabolism 610 $amicrobiota 610 $aMMP2 610 $amolecular ribbon 610 $amoxidectin 610 $amultifunctional PEG3 derivative 610 $an/a 610 $anatural product 610 $anatural product synthesis 610 $anatural remedy 610 $aNF-?B inhibition 610 $aNSCLC 610 $aobesity 610 $aonchocerciasis 610 $aosteoporosis 610 $aoverweight 610 $aPapaver somniferum (opium poppy) 610 $aPD-L1 610 $aphytocannabinoids 610 $aphytochemical 610 $aquinine 610 $arespiratory diseases 610 $asarcopenia 610 $aSARS-CoV-2 610 $asecondary metabolites 610 $aSTAT3 610 $asupramolecular self-assembly 610 $atanshinone IIA 610 $atetrahydrocannabinol (THC) 610 $athermos-TRPs 610 $atriterpenoid 610 $aTRPA1 610 $atumorsphere 610 $aUnited States Food and Drug Administration-approved drug 610 $aursolic acid 610 $avinblastine 610 $avincristine 610 $aviral fusion inhibitor 610 $a?,?-dimethylheptyl effect 610 $a?-ecdysone 615 7$aIndustrial chemistry and chemical engineering 615 7$aTechnology: general issues 700 $aDras?ar$b Pavel B$4edt$01303416 702 $aDras?ar$b Pavel B$4oth 906 $aBOOK 912 $a9910580203103321 996 $aTherapeutic Potential of Plant Secondary Metabolites in the Treatment of Diseases and Drug Development$93027019 997 $aUNINA